Congress Asset Management Co. Acquires 9,842 Shares of Repligen Co. (NASDAQ:RGEN)

Congress Asset Management Co. lifted its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 10.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 103,764 shares of the biotechnology company’s stock after purchasing an additional 9,842 shares during the quarter. Congress Asset Management Co. owned approximately 0.19% of Repligen worth $15,442,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of RGEN. Andra AP fonden acquired a new position in Repligen during the second quarter worth $25,000. International Assets Investment Management LLC bought a new position in shares of Repligen in the 2nd quarter valued at approximately $33,000. UMB Bank n.a. lifted its holdings in Repligen by 138.3% in the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares during the last quarter. Lazard Asset Management LLC boosted its position in Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares during the period. Finally, Blue Trust Inc. grew its holdings in Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 127 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Insider Activity at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.20% of the stock is owned by insiders.

Repligen Price Performance

NASDAQ:RGEN opened at $134.27 on Friday. The company has a 50-day moving average of $142.48 and a 200-day moving average of $146.23. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $211.13. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, hitting analysts’ consensus estimates of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The firm had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. During the same quarter last year, the company earned $0.53 earnings per share. The company’s revenue for the quarter was down 3.2% compared to the same quarter last year. As a group, research analysts forecast that Repligen Co. will post 1.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Wells Fargo & Company assumed coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price on the stock. UBS Group cut their price objective on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Stephens reaffirmed an “overweight” rating and issued a $170.00 target price on shares of Repligen in a report on Tuesday, July 30th. Benchmark reiterated a “hold” rating on shares of Repligen in a report on Monday, August 5th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $190.25.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.